Related Experiment Video
Updated: Aug 23, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate
Richard Choo1, Laurence Klotz, Gerrit Deboer
1Toronto-Sunnybrook Regional Cancer Center, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. richard.choo@tsrcc.on.ca
Objective:
To assess the prostate specific antigen (PSA) doubling time of untreated, clinically localized, low-to-intermediate grade prostate carcinoma.
Patients And Methods:
A prospective single-arm cohort study has been in progress since November 1995 to assess the feasibility of a watchful-observation protocol with selective delayed intervention for clinically localized, low-to-intermediate grade prostate adenocarcinoma. The PSA doubling time was estimated from a linear regression of ln(PSA) against time, assuming a simple exponential growth model.
Results:
As of March 2003, 231 patients had at least 6 months of follow-up (median 45) and at least three PSA measurements (median 8, range 3-21). The distribution of the doubling time was: < 2 years, 26 patients; 2-5 years, 65; 5-10 years, 42; 10-20 years, 26; 20-50 years, 16; >50 years, 56. The median doubling time was 7.0 years; 42% of men had a doubling time of >10 years.
Conclusions:
The doubling time of untreated clinically localized, low-to-intermediate grade prostate cancer varies widely.
